Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence.
Josip Andjelo BorovacMette Leth-OlsenMarko KumricDomenico D'AmarioKonstantin SchwarzDuska GlavasJosko BozicPublished in: European journal of clinical pharmacology (2021)
A high-dose loading of statins before PCI in patients with ACS reduces MACCE and reduces the risk of MI with no impact on mortality at 30 days. Atorvastatin reduces MACCE in STEMI while rosuvastatin reduces MACCE in NSTE-ACS at 30 days.
Keyphrases
- low dose
- high dose
- percutaneous coronary intervention
- acute coronary syndrome
- stem cell transplantation
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- antiplatelet therapy
- cardiovascular disease
- systematic review
- cardiovascular events
- type diabetes
- heart failure
- risk factors